Amedisys, Inc.

NasdaqGS:AMED Rapporto sulle azioni

Cap. di mercato: US$3.2b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Amedisys Gestione

Gestione criteri di controllo 1/4

Amedisys' Il CEO è Richard Ashworth, nominato in Apr2023, e ha un mandato di 1.33 anni. la retribuzione annua totale è $ 16.97M, composta da 4.1% di stipendio e 95.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.088% delle azioni della società, per un valore di $ 2.83M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 4.8 anni.

Informazioni chiave

Richard Ashworth

Amministratore delegato

US$17.0m

Compenso totale

Percentuale dello stipendio del CEO4.1%
Mandato del CEO1.4yrs
Proprietà del CEO0.09%
Durata media del management1.7yrs
Durata media del Consiglio di amministrazione4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Apr 10
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Feb 25
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Feb 10
Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jan 03
At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Dec 16
A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Nov 12
Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

Sep 19
Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04
An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04
Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20
We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04
At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05
Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06
Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20
Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19
Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18
These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18
Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28
Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02
It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Richard Ashworth rispetto agli utili di Amedisys?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

US$92m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$17mUS$692k

-US$10m

Compensazione vs Mercato: La retribuzione totale di Richard ($USD 16.97M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 6.76M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Richard con le performance aziendali.


AMMINISTRATORE DELEGATO

Richard Ashworth (49 yo)

1.4yrs

Mandato

US$16,974,025

Compensazione

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Richard Ashworth
President1.4yrsUS$16.97m0.088%
$ 2.8m
Scott Ginn
Executive VP6.9yrsUS$4.45m0.077%
$ 2.4m
Denise Bohnert
Chief Compliance Officer5yrsUS$1.28mNessun dato
Nick Muscato
Chief Strategy Officerno dataUS$1.37m0.0065%
$ 205.6k
Allyson Guidroz
Chief Accounting Officer & Principal Accounting Officer1.1yrsNessun dato0.0097%
$ 305.9k
Pete Hartley
CTO & Senior VP of Business Operations Systemsno dataNessun datoNessun dato
Jennifer Griffin
Senior VP1.9yrsNessun datoNessun dato
Kendra Kimmons
VP of Marketing & Communications & Media Relationsno dataNessun datoNessun dato
Caitlin Franklin
Acting Chief People Officerless than a yearNessun datoNessun dato
Francis Mayer
Senior Vice President of Developmentno dataNessun datoNessun dato

1.7yrs

Durata media

47.5yo

Età media

Gestione esperta: Il team dirigenziale di AMED non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Richard Ashworth
President1.4yrsUS$16.97m0.088%
$ 2.8m
Paul Kusserow
Chairman9.8yrsUS$4.00m1.33%
$ 42.2m
Bruce Perkins
Independent Director9.4yrsUS$267.62k0.063%
$ 2.0m
Vickie Capps
Independent Director4.8yrsUS$277.62k0.020%
$ 623.3k
Molly Coye
Independent Director4.8yrsUS$267.62k0.017%
$ 526.8k
Julie Klapstein
Lead Independent DIrector8.4yrsUS$282.62k0.039%
$ 1.2m
Jeffrey Rideout
Independent Director8.4yrsUS$267.62k0.018%
$ 576.7k
Teresa Kline
Independent Director4.8yrsUS$272.62k0.020%
$ 623.3k
Ivanetta Samuels
Independent Director3.8yrsUS$252.62k0.013%
$ 409.1k

4.8yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AMED sono considerati esperti (durata media dell'incarico 4.8 anni).